<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121820</url>
  </required_header>
  <id_info>
    <org_study_id>BIOMEM-20</org_study_id>
    <nct_id>NCT03121820</nct_id>
  </id_info>
  <brief_title>Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects</brief_title>
  <official_title>A Two-way Crossover, Open-label, Single-dose, Fasting, Bioequivalence Study of Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) 20 mg Tablets Versus Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany) 20 mg Tablets in Normal Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study are two-way crossover, open-label, single-dose, fasting, bioequivalence study of
      Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) 20 mg tablets versus Akatinol Memantine® (Merz Pharma
      GmbH &amp; Co. KGaA, Germany) 20 mg tablets in normal healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to evaluate the bioequivalence of orally administered memantinol preparations,
      film-coated tablets, 20 mg
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2016</start_date>
  <completion_date type="Actual">November 19, 2016</completion_date>
  <primary_completion_date type="Actual">November 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))</measure>
    <time_frame>0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of memantinol sourced in Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) and Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of memantinol sourced in Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) and Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Bioequivalence, AUC, Cmax, Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Memantinol tablets, 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC &quot;GEROPHARM&quot;, Russia - test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Akatinol Memantine® tablets, 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH &amp; Co. KGaA, Germany - reference)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantinol tablets, 20 mg</intervention_name>
    <description>Bioequivalence Memantine Hydrochloride (JSC &quot;GEROPHARM&quot;, Russia) 20 mg film-coated tablets fasting condition</description>
    <arm_group_label>Memantinol tablets, 20 mg</arm_group_label>
    <other_name>memantine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Akatinol Memantine® tablets, 20 mg</intervention_name>
    <description>Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH &amp; Co. KGaA, Germany) 20 mg film-coated tablets fasting condition</description>
    <arm_group_label>Akatinol Memantine® tablets, 20 mg</arm_group_label>
    <other_name>memantine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  Healthy male and female subjects aged 18 to 45 years.

          -  Verified diagnosis is &quot;healthy&quot; according to data Standard clinical, laboratory and
             Instrumental methods of examination.

          -  Have a body mass index between 18,5 and 27 kg/m2.

          -  Females must have a negative pregnancy test.

          -  Subjects must use, with their partner, methods of highly effective contraception; if
             the Hormonal contraceptives was used they must canceled have at least 2 month before
             the study.

        from the time of IMP administration until 3 months after the last dose of IMP.

        Exclusion Criteria:

          -  History of serious allergic problems/events

          -  Medicinal intolerance.

          -  History of allergic reactions to memantine or investigator's product components

          -  Any acute and chronic diseases of the cardiovascular system, cardiovascular,
             bronchopulmonary, neuroendocrinal systems, as well as diseases of the gastrointestinal
             tract, liver, kidneys, blood.

          -  Acute infectious diseases in less than 4 weeks before the start of the study.

          -  Subjects who have taken medication 4 weeks preceding before the study.

          -  Subjects who have taken any drugs known effects on hemodynamics or to induce or
             inhibit hepatic drug metabolism within 30 days prior to administration of the study
             medication (examples of inducers: barbiturates, omeprazole, etc.).

          -  Donation of plasma (450 mL or more) within 2 month prior to administration of the
             study medication.

          -  History of significant alcohol or drugs abuse or any indication of the regular use of
             more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or
             50 mL of alcohol 40%).

          -  Smokers.

          -  Participation in other clinical training is less than than for 3 months before the
             study.

          -  Lack of signed informed consent form.

          -  ECG or vital signs abnormalities (clinically significant).

          -  Positive testing for alcohol, drugs, pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Makarenko, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Igor.Makarenko@geropharm.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Clinical Hospital № 15 named. O.M.filatova</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <results_first_submitted>July 20, 2017</results_first_submitted>
  <results_first_submitted_qc>February 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2018</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited at GKB № 15 im. O. M. Filatova Public Healthcare Institution of Department of health care of Moscow, Russian Federation between October and November 2016</recruitment_details>
      <pre_assignment_details>18 participants recruited; 25 screened, 7 excluded (5 did not meet inclusion criteria and 2 refused participation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Memantinol First, Then Akatinol Memantine®</title>
          <description>First Intervention Period (3 day):
Memantinol tablet: Single administered dose of Memantinol ( 20 mg memantin) in a fasting state
(21 day washout period)
Second Intervention Period (3 day):
Akatinol Memantine® tablet: Single administered dose of Memantinol ( 20 mg memantin) in a fasting state</description>
        </group>
        <group group_id="P2">
          <title>Akatinol Memantine® First, Then Memantinol</title>
          <description>First Intervention Period (3 day):
Akatinol Memantine® tablet: Single administered dose of Memantinol ( 20 mg memantin) in a fasting state
(21 day washout period)
Second Intervention Period (3 day):
Memantinol tablet: Single administered dose of Memantinol ( 20 mg memantin) in a fasting state</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Period (After Washout)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Memantinol First, Then Akatinol Memantine®</title>
          <description>First Intervention Period (3 day):
Memantinol tablet: Single administered dose of Memantinol ( 20 mg memantin) in a fasting state
(21 day washout period)
Second Intervention Period (3 day):
Akatinol Memantine® tablet: Single administered dose of Memantinol ( 20 mg memantin) in a fasting state</description>
        </group>
        <group group_id="B2">
          <title>Akatinol Memantine® First, Then Memantinol</title>
          <description>First Intervention Period (3 day):
Akatinol Memantine® tablet: Single administered dose of Memantinol ( 20 mg memantin) in a fasting state
(21 day washout period)
Second Intervention Period (3 day):
Memantinol tablet: Single administered dose of Memantinol ( 20 mg memantin) in a fasting state</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))</title>
        <description>Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of memantinol sourced in Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) and Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany)</description>
        <time_frame>0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Memantinol Tablets, 20 mg</title>
            <description>Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC &quot;GEROPHARM&quot;, Russia - test)
Memantinol tablets, 20 mg: Bioequivalence Memantine Hydrochloride (JSC &quot;GEROPHARM&quot;, Russia) 20 mg film-coated tablets fasting condition</description>
          </group>
          <group group_id="O2">
            <title>Akatinol Memantine® Tablets, 20 mg</title>
            <description>Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH &amp; Co. KGaA, Germany - reference)
Akatinol Memantine® tablets, 20 mg: Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH &amp; Co. KGaA, Germany) 20 mg film-coated tablets fasting condition</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))</title>
          <description>Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of memantinol sourced in Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) and Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany)</description>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1920.362" spread="449.289"/>
                    <measurement group_id="O2" value="2096.669" spread="537.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The analysis was conducted using an analysis of variance (ANOVA) including fixed effects for treatment, sequence, period and subject within sequence. All pharmacokinetic parameters were log-transformed prior to analysis. Bioequivalence was concluded, when the 90% confidence interval (CI) for the geometric mean ratios were fully contained within the predefined equivalence limits of 80.00 % to 125.00 %</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Test/Ref Geometric mean ratio x 100</method>
            <method_desc>Bioequivalence is established when 90% Confidence Interval falls within 80.00 % -125.00 %.</method_desc>
            <param_type>Test/Ref Geometric mean ratio x 100</param_type>
            <param_value>93.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.25</ci_lower_limit>
            <ci_upper_limit>99.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)</title>
        <description>Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of memantinol sourced in Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) and Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany)</description>
        <time_frame>0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Memantinol Tablets, 20 mg</title>
            <description>Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC &quot;GEROPHARM&quot;, Russia - test)
Memantinol tablets, 20 mg: Bioequivalence Memantine Hydrochloride (JSC &quot;GEROPHARM&quot;, Russia) 20 mg film-coated tablets fasting condition</description>
          </group>
          <group group_id="O2">
            <title>Akatinol Memantine® Tablets, 20 mg</title>
            <description>Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH &amp; Co. KGaA, Germany - reference)
Akatinol Memantine® tablets, 20 mg: Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH &amp; Co. KGaA, Germany) 20 mg film-coated tablets fasting condition</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)</title>
          <description>Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of memantinol sourced in Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) and Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany)</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.617" spread="8.302"/>
                    <measurement group_id="O2" value="37.578" spread="8.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The analysis was conducted using an analysis of variance (ANOVA) including fixed effects for treatment, sequence, period and subject within sequence. All pharmacokinetic parameters were log-transformed prior to analysis. Bioequivalence was concluded, when the 90% confidence interval (CI) for the geometric mean ratios were fully contained within the predefined equivalence limits of 80.00 % to 125.00 %</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Test/Ref Geometric mean ratio x 100</method>
            <method_desc>Bioequivalence is established when 90% Confidence Interval falls within 80.00 % -125.00 %.</method_desc>
            <param_type>Test/Ref Geometric mean ratio x 100</param_type>
            <param_value>92.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.37</ci_lower_limit>
            <ci_upper_limit>98.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Memantinol Tablets, 20 mg</title>
          <description>Active experimental drug
Memantinol: Single orally administered dose of Memantinol (20 mg memantine) in a fasting state</description>
        </group>
        <group group_id="E2">
          <title>Akatinol Memantine® Tablets, 20 mg</title>
          <description>Active comparator
Akatinol Memantine®: Single orally administered dose of Akatinol Memantine® (20 mg memantine) in a fasting state</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>The volunteers during period, 2.5 hours after taking the test drug (20 mg orally) was dizzy. Deviations in any Analyzed indicators were not revealed. There was no volunteer Action taken. AE resolved full recovery.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from GEROPHARM will be obtained and a draft manuscript will be submitted to GEROPHARM for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and GEROPHARM.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GEROPHARM Clinical Leader</name_or_title>
      <organization>GEROPHARM</organization>
      <phone>+7(812) 703-79-75</phone>
      <email>inform@geropharm.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

